Tajenta-M 2.5 mg+850 mg (Tablet)

Therapeutic Class

• Combination Oral hypoglycemic preparations

Storage Conditions

• Keep in a cool & dry place (below 30°C), protected from light & moisture.
• Keep out of the reach of children.

Indications

• Improving glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise

Pharmacology

• Inhibitor of DPP-4 enzyme
• Increases concentrations of active incretin hormones
• Stimulates insulin release from pancreatic beta cells in a glucose-dependent manner
• Decreases glucagon secretion from pancreatic alpha cells
• Lowers basal and postprandial plasma glucose
• Decreases hepatic glucose production
• Decreases intestinal absorption of glucose
• Improves insulin sensitivity

Dosage & Administration

• Individualized dosage based on effectiveness and tolerability
• Maximum recommended dose of 2.5 mg Linagliptin and 1000 mg Metformin Hydrochloride twice daily with meals
• Dose escalation should be gradual
• Recommended starting dose based on patient's current treatment

Interaction

• Potential interaction with cationic drugs
• Risk of metabolic acidosis with carbonic anhydrase inhibitors
• Potential reduction in efficacy when administered with inducers of P-glycoprotein and CYP3A4 enzymes
• Careful observation for glycemic control when combined with specific drugs

Contraindications

• Contraindicated in patients with renal impairment
• Contraindicated in acute or chronic metabolic acidosis (diabetic ketoacidosis)
• Contraindicated in hypersensitivity to Linagliptin or Metformin Hydrochloride

Side Effects

• Most common side effects are nasopharyngitis and diarrhea
• Increased risk of hypoglycemia when used with sulfonylureas

Pregnancy & Lactation

• Should be used during pregnancy only if clearly needed
• Caution when administered to a lactating mother

Precautions & Warnings

• Discontinue immediately in cases of lactic acidosis
• Temporary discontinuation in specific medical procedures
• Monitoring of Vitamin B12 levels
• Prevention of hypoglycemia in various scenarios
• Careful adherence to health care team instructions

Overdose Effects

• Usual supportive measures in case of overdose
• Hemodialysis or peritoneal dialysis of Metformin Hydrochloride in overdose
• No dose-related clinical adverse drug reactions observed with Linagliptin
• Reported hypoglycemia and lactic acidosis in Metformin Hydrochloride overdose cases

Related Brands

• Linadus M XR 5 mg+1000 mg (Tablet (Extended Release)) - opsonin-pharma-ltd
• LG-M 2.5 mg+500 mg (Tablet) - silco-pharmaceutical-ltd
• Ligazid MX 5 mg+1000 mg (Tablet (Extended Release)) - eskayef-pharmaceuticals-ltd
• Renolina M 2.5 mg+850 mg (Tablet) - dbl-pharmaceuticals-ltd
• Renolina M 2.5 mg+500 mg (Tablet) - dbl-pharmaceuticals-ltd